A Phase 2 Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer (MBC) Who Have Received Prior HER2 Regimens for MBC
Phase of Trial: Phase II
Latest Information Update: 31 Mar 2016
At a glance
- Drugs Poziotinib (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Sponsors Spectrum Pharmaceuticals
- 07 Mar 2016 Status changed from not yet recruiting to recruiting, according to a Spectrum pharmaceuticals media release.
- 19 Jan 2016 Status changed from planning to not yet recruiting as reported by ClinicalTrials.gov.
- 23 Nov 2015 According to Spectrum media release, company has submitted an IND application to the US FDA.